The core considerations for pharmaceutical excipients center on four key aspects: regulatory compliance, safety, compatibility risks, and suitability for the intended route of administration.
Verify Grade and Regulatory Compliance
Only pharmaceutical-grade excipients-those listed in the Chinese Pharmacopoeia or filed with the Center for Drug Evaluation (CDE)-may be used; food-grade or industrial-grade alternatives are strictly prohibited.
Check accompanying documentation: Excipient labels must explicitly state "pharmaceutical excipient," and each shipment must include a complete quality inspection report.
Excipients intended for use in injectable or ophthalmic preparations are subject to significantly stricter compliance requirements, necessitating a formal supplier audit.
Ensure Safety and Manage Impurity Risks
Prioritize the use of inert excipients that possess stable physicochemical properties and lack significant pharmacological activity, thereby minimizing the physiological burden.
Scrutinize the impurity profile: Levels of elemental impurities, residual solvents, and genotoxic impurities must comply with established limits, such as those defined in ICH Q3D guidelines.
Substandard excipients may introduce heavy metals or harmful residues; long-term exposure can cause mucosal irritation and place an increased metabolic burden on the liver and kidneys.
Prevent Adverse Interactions with the Active Pharmaceutical Ingredient (API)
Certain excipients can diminish therapeutic efficacy; for example, Tween-80 may form insoluble complexes with tannins, leading to the precipitation and inactivation of the active ingredient.
The dosage of solubilizers and co-solubilizers must be strictly controlled: insufficient amounts fail to achieve the desired solubilization, while excessive amounts can hinder drug release.
During the formulation screening phase, comprehensive compatibility testing between the excipient and the API must be conducted to ensure the absence of issues such as adsorption, degradation, or precipitation.
